GSK plc (GS71.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 09:41PM CEST
| Previous close | 18.00 |
| Open | 18.01 |
| Bid | 17.92 x N/A |
| Ask | 18.19 x N/A |
| Day's range | 17.91 - 18.46 |
| 52-week range | 15.24 - 21.57 |
| Volume | |
| Avg. volume | 1,319 |
| Market cap | 73.175B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 13.88 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.70 (3.89%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Business Wire
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
- Business Wire
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer
- Business Wire
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
PHILADELPHIA, June 02, 2024--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma
© 2024 Yahoo. All rights reserved.